Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IAPP | P10997 | 2/20 | 0.58 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340131 | 0.89 | TDP1 (0.58) | IAPPCDYLMTNR1ATDP1KDM4E | |
| SCHEMBL696105 | 0.87 | MTNR1A (0.48) | IAPPCDYLMTNR1ATDP1KDM4E | |
| SCHEMBL9404001 | 0.86 | MTNR1A (0.58) | CDYLMTNR1ATDP1KDM4EGPR84 | |
| SCHEMBL6282199 | 0.83 | MTNR1A (0.50) | IAPPCDYLMTNR1ATDP1KDM4E | |
| SCHEMBL27891939 | 0.83 | TDP1 (0.51) | CDYLMTNR1ATDP1KDM4EGPR84 | |
| SCHEMBL4070603 | 0.82 | TDP1 (0.65) | TDP1KDM4EACP3CYP1A2CYP2C19 | |
| SCHEMBL29875700 | 0.82 | TDP1 (0.65) | TDP1KDM4EACP3CYP1A2CYP2C19 | |
| SCHEMBL4070601 | 0.82 | IAPP (0.56) | IAPPCDYLMTNR1ATDP1KDM4E | |
| SCHEMBL30258002 | 0.82 | IAPP (0.56) | IAPPCDYLMTNR1ATDP1KDM4E | |
| SCHEMBL14608998 | 0.82 | MTNR1A (0.49) | IAPPCDYLMTNR1ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, PREP | IAPP 1306/4885CDYL 4651/4885MTNR1A 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.